Jazz Pharmaceuticals PLC
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +1.7% | -0.6% | +0.3% | +7.9% | -2.0% | -4.0% | -5.1% | +3.8% | +2.7% | +1.7% | -6.6% | |
| – | +0.6% | +8.5% | +4.0% | +19.3% | +5.4% | -10.8% | -18.8% | +12.1% | +10.9% | +10.0% | -13.4% | |
| – | -9.7% | +19.7% | -6.1% | +63.6% | +8.8% | -22.8% | -36.1% | +3.9% | +12.6% | +32.5% | -12.2% | |
| – | +2.6% | +11.8% | +8.9% | +32.2% | +14.3% | -14.1% | -35.1% | +22.5% | +19.3% | +17.7% | -23.5% | |
| – | +12.4% | +0.2% | -1.3% | +3.7% | -0.9% | -8.9% | +9.3% | +7.1% | +8.7% | +0.7% | +5.3% | |
| – | -2.4% | -3.3% | -6.0% | -0.6% | -10.9% | +2.6% | +2.5% | -4.3% | -13.7% | +4.9% | +1.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +2.8% | -0.8% | -0.2% | +4.0% | -4.9% | +2.5% | +4.8% | -0.9% | +0.1% | -1.3% | -0.3% | |
| – | +0.0% | -3.4% | -3.0% | +1.3% | -7.6% | -0.8% | +1.1% | -4.3% | -3.0% | -5.1% | -4.1% | |
| – | -0.8% | -0.3% | -0.4% | +6.4% | -2.1% | -7.1% | -1.7% | +2.2% | -0.8% | -0.2% | -14.3% | |
| – | -2.3% | +1.7% | -0.4% | -33.8% | +0.8% | +17.7% | +69.4% | +9.8% | -1.4% | +0.2% | -0.7% | |
| – | +0.5% | -0.1% | -0.1% | -92.0% | -8.6% | -2.9% | +2,245.3% | +0.1% | +0.1% | +0.1% | -1.4% | |
| – | -6.5% | -21.2% | +19.9% | -12.0% | -8.8% | +23.2% | -6.8% | +70.3% | -19.8% | -18.1% | +28.5% | |
| – | -0.1% | -0.1% | -0.1% | +19.2% | -0.1% | -12.2% | -18.8% | -0.1% | -0.1% | -0.1% | -22.9% | |
| – | +7.1% | -1.1% | +1.8% | +10.9% | -1.9% | +2.0% | -11.2% | +6.8% | +9.1% | +4.9% | +5.9% | |
| – | -0.6% | -1.7% | +0.8% | +7.5% | +20.4% | -8.2% | -81.5% | +131.4% | +46.0% | +45.3% | +20.5% | |
| – | -2.3% | -10.2% | +11.3% | -9.3% | -2.6% | -0.9% | +0.4% | +0.7% | -1.0% | +8.4% | +5.0% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.